Cisplatin and etoposide (EP-regimen) is superior to cyclophosphamide, epirubicin, and vincristin (CEV-regimen) in small cell lung cancer: results from a randomized phase III trial with 5 years follow-up

Sundstrøm, Stein; Bremnes, Roy M.; Kaasa, Stein; Aamdal, S.

doi:10.1016/s0959-8049(01)81048-0

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second-line crossover treatment was nonrandomised and thus subjected to the risk of selection bias. Moreover the relapse study population may be considered a selected subgroup since only a limited part (42%) of the initially treated patient population were considered to be suitable for second-line chemotherapy at the time of disease progression [6]. When compared to the best supportive care group, the second-line chemotherapy group survived significantly longer.…”

Section: Discussionmentioning

confidence: 99%

“…EP chemotherapy is considered the standard first-line regimen in SCLC [6][7][8], while there still is no consensus on second-line therapy. Though no randomised phase III trial hitherto has compared chemotherapy or best supportive care in recurrent SCLC, there is consensus that these patients, if considered fit, should be offered secondline chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Among 436 patients previously treated with EP or CEV in a randomised fashion [6], detailed follow-up information regarding recurrence and re-treatment were available in 382 patients (88%). Of these, 286 patients (75%) were diagnosed with relapse of which 120 received further chemotherapy.…”

Section: Patients Eligibility and Stagingmentioning

confidence: 99%

“…Combination chemotherapy with cisplatin and etoposide (EP-regimen) is accepted as the standard regimen in SCLC, regardless of disease stage [6][7][8]. However, anthracyclin-based regimens with cyclophosphamide, doxorubicin, and vincristin (CAVregimen) have been widely used due to treatment tradition and more convenient administration.…”

Section: Introductionmentioning

confidence: 99%

“…The original study was initiated with the main objective to evaluate, in a randomised fashion, whether EP was superior to the three-drug combination of CEV (cyclophosphamide, epirubicin and vincristin) [6]. The protocol recommended crossover-therapy with the alternative regimen at relapse.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Second-line chemotherapy in recurrent small cell lung cancer

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Patients Eligibility and Stagingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Second-line chemotherapy in recurrent small cell lung cancer

et al. 2005

View full text Add to dashboard Cite

Small Cell Lung Cancer: Limited Disease

Houtte¹,

Roelandts²,

Cappello³

et al. 2004

Malignant Tumors of the Lung

View full text Add to dashboard Cite

Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model

Gao

Dang

et al. 2020

Medicine

View full text Add to dashboard Cite

This study is to establish the nomogram model and provide clinical therapy decision-making for extensive-stage small-cell lung cancer (ES-SCLC) patients with different metastatic sites using the Surveillance, Epidemiology, and End Results (SEER) Program. A total of 10,025 patients of ES-SCLC with metastasis from January 2010 to December 2016 were enrolled from the SEER database. All samples were randomly divided into a derivation cohort and a validation cohort, and the derivation cohort was divided into 6 groups by different metastatic sites: bone, liver, lung, brain, multiple organs, and other organs. Using Cox proportional hazards models to analyze candidate prognostic factors, screening out the independent prognostic factors to establish the nomogram. Compare the different models by Net reclassification improvement and integrated discrimination improvement. Concordance index (C-index) and the calibration curve were used to verify the prediction efficiency of the nomogram in the derivation cohort and validation cohort. In the derivation cohort, the median overall survival was 7 months. The overall survival rates at 6-month, 1-year, and 2-year were 55.07%, 24.61%, and 7.56%, respectively. The median survival time was 10, 8, 7, 9, 7, and 6 months for the 6 groups of different metastatic sites: other, bone, liver, lung, brain, and multiple organs, respectively. Age, sex, race, T, N, distant metastatic site, and chemotherapy were contained in the final nomogram prognostic model. The C-index was 0.6569777 in the derivation cohort and 0.8386301 in the validation cohort. The survival time of ES-SCLC patients with different metastatic sites was significantly different. The nomogram can effectively predict the prognosis of individuals and provide a basis for clinical decision-making.

show abstract

Cisplatin and etoposide (EP-regimen) is superior to cyclophosphamide, epirubicin, and vincristin (CEV-regimen) in small cell lung cancer: results from a randomized phase III trial with 5 years follow-up

Cited by 4 publications

References 0 publications

Second-line chemotherapy in recurrent small cell lung cancer

Second-line chemotherapy in recurrent small cell lung cancer

Small Cell Lung Cancer: Limited Disease

Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model

Contact Info

Product

Resources

About